Rice Hall James & Associates’s Antares Pharma, Inc. ATRS Stock Holding History

Rice Hall James & Associates’s Portfolio ATRS Stock Details ATRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,218,851	Closed	-$5M	–	312
2022 Q1	$5M	Buy	1,218,851 +7,500	+0.6%	+$27.2K	0.2%	98
2021 Q4	$4.33M	Buy	1,211,351 +534,664	+79%	+$1.87M	0.15%	132
2021 Q3	$2.46M	Sell	676,687 -1,996	-0.3%	-$8.07K	0.09%	173
2021 Q2	$2.96M	Sell	678,683 -22,816	-3%	-$92.9K	0.11%	149
2021 Q1	$2.88M	Buy	701,499 +101,871	+17%	+$441K	0.09%	152
2020 Q4	$2.39M	Buy	+599,628	New	+$1.94M	0.08%	161

Other funds holding ATRS

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

Rice Hall James & Associates's ATRS Position: Q2 2022 in Review

Rice Hall James & Associates sold out of Antares Pharma, Inc. (ATRS) in Q2 2022, closing a stake of 1,218,851 shares — an estimated $5M sold.

Rice Hall James & Associates first reported a position in ATRS in Q4 2020 and held it in 6 quarters. The position peaked at $5M in Q1 2022. 1 fund tracked by Wall St. Rank holds ATRS as of Q2 2022.

Rice Hall James & Associates reported no remaining Antares Pharma, Inc. position as of Q2 2022 after selling out during the quarter.
Rice Hall James & Associates sold 1,218,851 Antares Pharma, Inc. shares in Q2 2022, an estimated $5M.
Rice Hall James & Associates first reported a position in Antares Pharma, Inc. in Q4 2020 and held it in 6 quarters.
Rice Hall James & Associates's Antares Pharma, Inc. position peaked at $5M in Q1 2022.
1 fund tracked by Wall St. Rank held Antares Pharma, Inc. as of Q2 2022.

Based on Rice Hall James & Associates's 13F filing for Q2 2022, filed 8 Aug 2022.